Pulmonary Hypertension News – Pulmonary Hypertension News
2025年1月13日 · Winrevair regimen balances efficacy, safety in PAH: Analysis. The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows.
Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
2019年7月8日 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
Winrevair regimen balances efficacy, safety in PAH: Analysis
2025年1月17日 · The dosing regimen for Winrevair (sotatercept-csrk) is optimal for balancing efficacy and safety in adults with pulmonary arterial hypertension (PAH), an analysis of clinical trial data shows. This regimen is “well-justified based on the totality of the observed safety and efficacy data from Phase ...
Adempas helps lower risk in PAH patients, newer risk model …
4 天之前 · People with pulmonary arterial hypertension (PAH) seen to be at an intermediate risk of death — whether in the low or high range of that middle-level risk — were more likely to have better outcomes when treated with Adempas (riociguat) than given a placebo in a Phase 3 clinical trial, its data show.
Approval of new treatments for pulmonary hypertension prompts...
2024年4月3日 · First, in late March, the FDA approved a once-daily, fixed-dose tablet containing a combination of macitentan and tadalafil for adults with pulmonary arterial hypertension (PAH). It will be marketed under the brand name Opsynvi and is the first single-tablet treatment combination to become available to people with PAH in the U.S.. Then, just days later, the FDA approved the under-the-skin ...
Model predicts sotatercept will extend survival in PAH patients
2023年11月8日 · The prediction model was built using short-term data from the Phase 3 STELLAR clinical trial (NCT04576988) of sotatercept as well as real-world outcomes from PAH patient registries.. While long-term information about the effects of sotatercept is not yet available, the analysis informs on its possible survival benefits for people with PAH.
Top 10 Pulmonary Hypertension Stories of 2022 | Key Topics:...
2022年12月29日 · Opsumit (macitentan) is a daily oral therapy that’s approved to treat pulmonary arterial hypertension (PAH). In this study, researchers analyzed data from the Phase 3 clinical trial SERAPHIN (NCT00660179) and its open-label extension (NCT00667823) to evaluate the therapy’s long-term effect on survival.Nearly three-quarters (73.3%) of patients were alive at five years, and more than half ...
Updated PAH Treatment Guidelines Released by CHEST
2019年2月13日 · The free guide, titled “ Therapy for Pulmonary Arterial Hypertension in Adults 2018: Update of the CHEST Guideline and Expert Panel Report, ” was published in the journal Chest. PAH is a progressive lung disorder caused by increased pressure in the lung blood vessels. Available treatment options for the disease help alleviate the pressure, reduce inflammation, and improve blood flow.
Top 10 Pulmonary Hypertension Stories of 2021 – Pulmonary...
2022年1月3日 · The U.S. Food and Drug Administration (FDA), however, declined to approve Tyvaso DPI in October due to an inspection issue at a third-party manufacturing facility. United Therapeutics announced an intention to address this single issue. No. 6 – “Uptravi Found to Reduce Risk, by Half, of PAH Disease Progression“ The Phase 3 clinical trials GRIPHON (NCT01106014) and TRITON (NCT02558231 ...
The management of pulmonary hypertension is a long road
2023年8月18日 · A typical visit goes as follows: Check in, take vital signs, conduct a six-minute walk test (while subconsciously trying to beat the numbers for a previous effort), and undergo an echocardiogram, a chest X-ray, and various labs.The results vary but rarely improve significantly, which would be a dream come true for a PAH patient.